PledPharma AB (publ) Stock Nasdaq Stockholm
Equities
SE0003815604
Biotechnology & Medical Research
Sales 2024 * | 60.99M 5.79M | Sales 2025 * | 491M 46.68M | Capitalization | 1.59B 151M |
---|---|---|---|---|---|
Net income 2024 * | -293M -27.84M | Net income 2025 * | 107M 10.17M | EV / Sales 2024 * | 24.3 x |
Net cash position 2024 * | 105M 9.94M | Net cash position 2025 * | 229M 21.72M | EV / Sales 2025 * | 2.76 x |
P/E ratio 2024 * |
-5.3
x | P/E ratio 2025 * |
12.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.24% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 21-03-31 |
1st Jan change | Capi. | |
---|---|---|
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |